Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 181-191

  Jabs, A ^a   Oelze, M ^a   Mikhed, Y ^a   Stamm, P ^a   Kroller Schon S ^a   Welschof, P ^a   Jansen, T ^a   Hausding, M ^a   Kopp, M ^a   Steven, S ^a   Schulz, E ^a   Stasch, J P ^b   Munzel T ^a   Daiber, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Endothelial dysfunction; Nitroglycerin tolerance; Oxidative stress; SGC activator; SGC stimulator

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; BAY 60 2770; CYCLIC GMP; GLYCERYL TRINITRATE; GUANYLATE CYCLASE ACTIVATOR; NITRATE; NITRIC OXIDE; PROTEIN KINASE; SOLUBLE GUANYLYL CYCLASE ACTIVATOR; UNCLASSIFIED DRUG; 4-(((4-CARBOXYBUTYL) (2- (5-FLUORO-2-((4'-(TRIFLUOROMETHYL) BIPHENYL-4-YL)METHOXY)PHENYL)ETHYL) AMINO)METHYL)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; CELL RECEPTOR; FLUORINATED HYDROCARBON; GUANYLATE CYCLASE; MORPHOLINE DERIVATIVE; NITRIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VASCULAR RING; VASCULAR TISSUE; ANIMAL; AORTA; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; WISTAR RAT;

ANIMALS; AORTA; BENZOATES; BIPHENYL COMPOUNDS; ENZYME ACTIVATION; GUANYLATE CYCLASE; HYDROCARBONS, FLUORINATED; MALE; MORPHOLINES; NITRATES; NITROGLYCERIN; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84937977181     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.03.007     Document Type: Article

References (76)

1. Task Force Members, Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34:2949-3003.
2. Munzel T., Daiber A., Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011, 123:2132-2144.
3. Munzel T., Daiber A., Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J 2013, 34:2666-2673.
4. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995, 95:187-194.
5. Kaesemeyer W.H., Ogonowski A.A., Jin L., Caldwell R.B., Caldwell R.W. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate. Br J Pharmacol 2000, 131:1019-1023.
6. Mihm M.J., Coyle C.M., Jing L., Bauer J.A. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther 1999, 291:194-198.
7. Bassenge E., Fink N., Skatchkov M., Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998, 102:67-71.
8. Watanabe H., Kakihana M., Ohtsuka S., Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997, 96:2545-2550.
9. Elkayam U. Prevention of nitrate tolerance with concomitant administration of hydralazine. Can J Cardiol 1996, 12(Suppl. C):17C-21C.
10. Daiber A., Oelze M., Coldewey M., Kaiser K., Huth C., Schildknecht S., et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 2005, 338:1865-1874.
11. Sydow K., Daiber A., Oelze M., Chen Z., August M., Wendt M., et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004, 113:482-489.
12. Wenzel P., Mollnau H., Oelze M., Schulz E., Wickramanayake J.M., Muller J., et al. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal 2008, 10:1435-1447.
13. Kurz S., Hink U., Nickenig G., Borthayre A.B., Harrison D.G., Munzel T. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999, 99:3181-3187.
14. Daiber A., Oelze M., Sulyok S., Coldewey M., Schulz E., Treiber N., et al. Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol 2005, 68:579-588.
15. Knorr M., Hausding M., Kroller-Schuhmacher S., Steven S., Oelze M., Heeren T., et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol 2011, 31:2223-2231.
16. Munzel T., Li H., Mollnau H., Hink U., Matheis E., Hartmann M., et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000, 86:E7-E12.
17. Oelze M., Knorr M., Schell R., Kamuf J., Pautz A., Art J., et al. Regulation of human mitochondrial aldehyde dehydrogenase (ALDH-2) activity by electrophiles in vitro. J Biol Chem 2011, 286:8893-8900.
18. Wenzel P., Hink U., Oelze M., Schuppan S., Schaeuble K., Schildknecht S., et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 2007, 282:792-799.
19. Daiber A., Oelze M., Coldewey M., Bachschmid M., Wenzel P., Sydow K., et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 2004, 66:1372-1382.
20. Rapoport R.M., Waldman S.A., Ginsburg R., Molina C.R., Murad F. Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 1987, 10:82-89.
21. Munzel T., Daiber A., Ullrich V., Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 2005, 25:1551-1557.
22. Mulsch A., Oelze M., Kloss S., Mollnau H., Topfer A., Smolenski A., et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001, 103:2188-2194.
23. Brune B., Schmidt K.U., Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 1990, 192:683-688.
24. Weber M., Lauer N., Mulsch A., Kojda G. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med 2001, 31:1360-1367.
25. Stasch J.P. Schmidt, P. M.; Nedvetsky, P. I.; Nedvetskaya, T. Y.; H, S. A.; Meurer, S.; Deile, M.; Taye, A.; Knorr, A.; Lapp, H.; Muller, H.; Turgay, Y.; Rothkegel, C.; Tersteegen, A.; Kemp-Harper, B.; Muller-Esterl, W.; Schmidt, H. H. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006, 116:2552-2561.
26. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5:755-768.
27. Mitrovic V., Hernandez A.F., Meyer M., Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 2009, 14:309-319.
28. Mielniczuk L.M., Swiston J.R., Mehta S. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Can J Cardiol 2014, 30:1233-1240.
29. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011, 123:2263-2273.
30. Follmann M., Griebenow N., Hahn M.G., Hartung I., Mais F.J., Mittendorf J., et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem 2013, 52:9442-9462.
31. Stasch J.P., Evgenov O.V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013, 218:279-313.
32. Kleschyov A.L., Munzel T. Advanced spin trapping of vascular nitric oxide using colloid iron diethyldithiocarbamate. Methods Enzymol 2002, 359:42-51.
33. Kroller-Schon S., Steven S., Kossmann S., Scholz A., Daub S., Oelze M., et al. Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 2014, 20:247-266.
34. Hausding M., Jurk K., Daub S., Kroller-Schon S., Stein J., Schwenk M., et al. CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol 2013, 108:386.
35. Kroller-Schon S., Jansen T., Schuler A., Oelze M., Wenzel P., Hausding M., et al. Peroxisome proliferator-activated receptor gamma, coactivator 1alpha deletion induces angiotensin II-associated vascular dysfunction by increasing mitochondrial oxidative stress and vascular inflammation. Arterioscler Thromb Vasc Biol 2013, 33:1928-1935.
36. Schulz E., Tsilimingas N., Rinze R., Reiter B., Wendt M., Oelze M., et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002, 105:1170-1175.
37. Mollace V., Muscoli C., Dagostino C., Giancotti L.A., Gliozzi M., Sacco I., et al. The effect of peroxynitrite decomposition catalyst MnTBAP on aldehyde dehydrogenase-2 nitration by organic nitrates: role in nitrate tolerance. Pharmacol Res 2014, 89:29-35.
38. Daiber A., Munzel T., Gori T. Organic nitrates and nitrate tolerance-state of the art and future developments. Adv Pharmacol 2010, 60:177-227.
39. Munzel T., Daiber A., Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005, 97:618-628.
40. Fleming I., Fisslthaler B., Dimmeler S., Kemp B.E., Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001, 88:E68-E75.
41. Loot A.E., Schreiber J.G., Fisslthaler B., Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 2009, 206:2889-2896.
42. Hink U., Oelze M., Kolb P., Bachschmid M., Zou M.H., Daiber A., et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 2003, 42:1826-1834.
43. Liu S., Ngo D.T., Stewart S., Horowitz J.D., Chirkov Y.Y. B-Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects. Clin Exp Pharmacol Physiol 2014, 41:739-743.
44. Weissmann N., Lobo B., Pichl A., Parajuli N., Seimetz M., Puig-Pey R., et al. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med 2014, 189:1359-1373.
45. Wang W.Z., Jones A.W., Wang M., Durante W., Korthuis R.J. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice. Am J Physiol Heart Circ Physiol 2013, 305:H521-H532.
46. Raat N.J., Tabima D.M., Specht P.A., Tejero J., Champion H.C., Kim-Shapiro D.B., et al. Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction. Antioxid Redox Signal 2013, 19:2232-2243.
47. Tawa M., Geddawy A., Shimosato T., Iwasaki H., Imamura T., Okamura T. Soluble guanylate cyclase redox state under hypoxia or hypoxia/reoxygenation in isolated monkey coronary arteries. J Pharmacol Sci 2014, 125:169-175.
48. Watts J.A., Gellar M.A., Fulkerson M.B., Kline J.A. Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543. Crit Care Med 2011, 39:2700-2704.
49. Stasch J.P., Dembowsky K., Perzborn E., Stahl E., Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 2002, 135:344-355.
50. Stasch J.P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002, 135:333-343.
51. Stasch J.P., Schmidt P., Alonso-Alija C., Apeler H., Dembowsky K., Haerter M., et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002, 136:773-783.
52. Riego J.A., Broniowska K.A., Kettenhofen N.J., Hogg N. Activation and inhibition of soluble guanylyl cyclase by S-nitrosocysteine: involvement of amino acid transport system L. Free Radic Biol Med 2009, 47:269-274.
53. Fernhoff N.B., Derbyshire E.R., Underbakke E.S., Marletta M.A. Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide. J Biol Chem 2012, 287:43053-43062.
54. Mayer B., Kleschyov A.L., Stessel H., Russwurm M., Munzel T., Koesling D., et al. Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol Pharmacol 2009, 75:886-891.
55. Crassous P.A., Couloubaly S., Huang C., Zhou Z., Baskaran P., Kim D.D., et al. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol 2012, 303:H597-H604.
56. Sayed N., Kim D.D., Fioramonti X., Iwahashi T., Duran W.N., Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008, 103:606-614.
57. Kumar V., Martin F., Hahn M.G., Schaefer M., Stamler J.S., Stasch J.P., et al. Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry 2013, 52:3601-3608.
58. Wenzel P., Oelze M., Coldewey M., Hortmann M., Seeling A., Hink U., et al. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 2007, 27:1729-1735.
59. Oberle S., Abate A., Grosser N., Hemmerle A., Vreman H.J., Dennery P.A., et al. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood) 2003, 228:529-534.
60. Oberle S., Abate A., Grosser N., Vreman H.J., Dennery P.A., Schneider H.T., et al. Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate. Biochem Biophys Res Commun 2002, 290:1539-1544.
61. Schuhmacher S., Wenzel P., Schulz E., Oelze M., Mang C., Kamuf J., et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010, 55:897-904.
62. Otto A., Fontaine D., Fontaine J., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 2005, 46:177-184.
63. Fontaine D., Otto A., Fontaine J., Berkenboom G. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther 2003, 17:123-128.
64. Munzel T., Kurz S., Rajagopalan S., Thoenes M., Berrington W.R., Thompson J.A., et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996, 98:1465-1470.
65. Warnholtz A., Mollnau H., Heitzer T., Kontush A., Moller-Bertram T., Lavall D., et al. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 2002, 40:1356-1363.
66. Ikejima H., Imanishi T., Tsujioka H., Kuroi A., Muragaki Y., Mochizuki S., et al. Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor. Circ J 2008, 72:998-1002.
67. Hink U., Daiber A., Kayhan N., Trischler J., Kraatz C., Oelze M., et al. Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol 2007, 50:2226-2232.
68. Sage P.R., de la Lande I.S., Stafford I., Bennett C.L., Phillipov G., Stubberfield J., et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000, 102:2810-2815.
69. Caramori P.R., Adelman A.G., Azevedo E.R., Newton G.E., Parker A.B., Parker J.D. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998, 32:1969-1974.
70. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al-Hesayen A., Kelly S., et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001, 104:1119-1123.
71. Gori T., Harvey P., Floras J.S., Parker J.D. Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol 2004, 44:601-606.
72. Liuni A., Luca M.C., Di Stolfo G., Uxa A., Mariani J.A., Gori T., et al. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. J Am Coll Cardiol 2011, 57:93-98.
73. Molina C.R., Andresen J.W., Rapoport R.M., Waldman S., Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 1987, 10:371-378.
74. Stewart D.J., Holtz J., Bassenge E. Long-term nitroglycerin treatment: effect on direct and endothelium-mediated large coronary artery dilation in conscious dogs. Circulation 1987, 75:847-856.
75. Wenzl M.V., Wolkart G., Stessel H., Beretta M., Schmidt K., Mayer B. Different effects of ascorbate deprivation and classical vascular nitrate tolerance on aldehyde dehydrogenase-catalysed bioactivation of nitroglycerin. Br J Pharmacol 2009, 156:1248-1255.
76. Wolkart G., Wenzl M.V., Beretta M., Stessel H., Schmidt K., Mayer B. Vascular tolerance to nitroglycerin in ascorbate deficiency. Cardiovasc Res 2008, 79:304-312.